194 related articles for article (PubMed ID: 18565156)
1. Prediction of serotonergic treatment efficacy using age of onset and Type A/B typologies of alcoholism.
Roache JD; Wang Y; Ait-Daoud N; Johnson BA
Alcohol Clin Exp Res; 2008 Aug; 32(8):1502-12. PubMed ID: 18565156
[TBL] [Abstract][Full Text] [Related]
2. Ondansetron reduces the craving of biologically predisposed alcoholics.
Johnson BA; Roache JD; Ait-Daoud N; Zanca NA; Velazquez M
Psychopharmacology (Berl); 2002 Apr; 160(4):408-13. PubMed ID: 11919668
[TBL] [Abstract][Full Text] [Related]
3. Ondansetron reduces mood disturbance among biologically predisposed, alcohol-dependent individuals.
Johnson BA; Ait-Daoud N; Ma JZ; Wang Y
Alcohol Clin Exp Res; 2003 Nov; 27(11):1773-9. PubMed ID: 14634493
[TBL] [Abstract][Full Text] [Related]
4. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial.
Johnson BA; Roache JD; Javors MA; DiClemente CC; Cloninger CR; Prihoda TJ; Bordnick PS; Ait-Daoud N; Hensler J
JAMA; 2000 Aug 23-30; 284(8):963-71. PubMed ID: 10944641
[TBL] [Abstract][Full Text] [Related]
5. Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence.
Ait-Daoud N; Johnson BA; Prihoda TJ; Hargita ID
Psychopharmacology (Berl); 2001 Feb; 154(1):23-7. PubMed ID: 11292002
[TBL] [Abstract][Full Text] [Related]
6. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence.
Johnson BA; Ait-Daoud N; Prihoda TJ
Alcohol Clin Exp Res; 2000 May; 24(5):737-42. PubMed ID: 10832917
[TBL] [Abstract][Full Text] [Related]
7. Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study.
Kranzler HR; Pierucci-Lagha A; Feinn R; Hernandez-Avila C
Alcohol Clin Exp Res; 2003 Jul; 27(7):1150-5. PubMed ID: 12878921
[TBL] [Abstract][Full Text] [Related]
8. Effects of alcoholism typology on response to naltrexone in the COMBINE study.
Bogenschutz MP; Scott Tonigan J; Pettinati HM
Alcohol Clin Exp Res; 2009 Jan; 33(1):10-8. PubMed ID: 18828797
[TBL] [Abstract][Full Text] [Related]
9. Combining ondansetron and naltrexone treats biological alcoholics: corroboration of self-reported drinking by serum carbohydrate deficient transferrin, a biomarker.
Ait-Daoud N; Johnson BA; Javors M; Roache JD; Zanca NA
Alcohol Clin Exp Res; 2001 Jun; 25(6):847-9. PubMed ID: 11410720
[TBL] [Abstract][Full Text] [Related]
10. A multi-site study of alcohol subtypes: classification and overlap of unidimensional and multi-dimensional typologies.
Epstein EE; Labouvie E; McCrady BS; Jensen NK; Hayaki J
Addiction; 2002 Aug; 97(8):1041-53. PubMed ID: 12144607
[TBL] [Abstract][Full Text] [Related]
11. A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism.
Kampman KM; Pettinati HM; Lynch KG; Whittingham T; Macfadden W; Dackis C; Tirado C; Oslin DW; Sparkman T; O'Brien CP
J Clin Psychopharmacol; 2007 Aug; 27(4):344-51. PubMed ID: 17632217
[TBL] [Abstract][Full Text] [Related]
12. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics.
Kranzler HR; Burleson JA; Brown J; Babor TF
Alcohol Clin Exp Res; 1996 Dec; 20(9):1534-41. PubMed ID: 8986200
[TBL] [Abstract][Full Text] [Related]
13. The role of serotonergic agents as treatments for alcoholism.
Johnson BA
Drugs Today (Barc); 2003 Sep; 39(9):665-72. PubMed ID: 14586482
[TBL] [Abstract][Full Text] [Related]
14. Role of the serotonergic system in the neurobiology of alcoholism: implications for treatment.
Johnson BA
CNS Drugs; 2004; 18(15):1105-18. PubMed ID: 15581381
[TBL] [Abstract][Full Text] [Related]
15. Types of alcoholics, I. Evidence for an empirically derived typology based on indicators of vulnerability and severity.
Babor TF; Hofmann M; DelBoca FK; Hesselbrock V; Meyer RE; Dolinsky ZS; Rounsaville B
Arch Gen Psychiatry; 1992 Aug; 49(8):599-608. PubMed ID: 1637250
[TBL] [Abstract][Full Text] [Related]
16. Applications of Cloninger's subtypes in a female alcoholic sample.
Glenn SW; Nixon SJ
Alcohol Clin Exp Res; 1991 Oct; 15(5):851-7. PubMed ID: 1755519
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking.
Johnson BA; Ait-Daoud N; Seneviratne C; Roache JD; Javors MA; Wang XQ; Liu L; Penberthy JK; DiClemente CC; Li MD
Am J Psychiatry; 2011 Mar; 168(3):265-75. PubMed ID: 21247998
[TBL] [Abstract][Full Text] [Related]
18. Treatment outcomes in type A and B alcohol dependence 6 months after serotonergic pharmacotherapy.
Dundon W; Lynch KG; Pettinati HM; Lipkin C
Alcohol Clin Exp Res; 2004 Jul; 28(7):1065-73. PubMed ID: 15252293
[TBL] [Abstract][Full Text] [Related]
19. Marital functioning in early versus late-onset alcoholic couples.
Epstein EE; McCrady BS; Hirsch LS
Alcohol Clin Exp Res; 1997 May; 21(3):547-56. PubMed ID: 9161616
[TBL] [Abstract][Full Text] [Related]
20. Typologies of alcohol dependence. From Jellinek to genetics and beyond.
Leggio L; Kenna GA; Fenton M; Bonenfant E; Swift RM
Neuropsychol Rev; 2009 Mar; 19(1):115-29. PubMed ID: 19184441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
